FOR IMMEDIATE RELEASE

APPLIED PROTEOMICS INC. ANNOUNCES THREE ADDITIONAL DATA SETS THAT FURTHER VALIDATE ITS LINUS™ TECHNOLOGY, A PROTEIN DISCOVERY AND TEST DELIVERY ENGINE

Company to Present New Data at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo

---

SAN DIEGO, Calif., July 31, 2017 – Applied Proteomics, Inc. (API), an innovation technology company that leverages the power of the proteome for monitoring health and early detection of disease, today announced that its Linus™ technology has been further validated via the addition of three new data sets that will be presented as scientific posters at the AACC Annual Scientific Meeting & Clinical Lab Expo being held in San Diego, CA (July 30 – August 3, 2017). The data support the second generation of Linus' first commercial application – the SimpliPro Colon test, which is a blood-based test that assesses the risk of colorectal cancer in elevated-risk patients. The data, which include clinical validation, demonstrate the test's performance; its analytical validation to provide continued reliable results; and the modular automation of the multiplexed immunoassay increasing the overall throughput.

"These new data sets continue to validate our Linus technology as a protein discovery and test delivery engine that brings real-world clinical value," said Bruce Wilcox, PhD, Senior Vice President, Research & Development, API. "These data demonstrate Linus' capability to provide high-quality analysis, while crossing cohorts and technology platforms to expedite the clinical application," Wilcox added.

"We've achieved an early key milestone in validating our Linus platform for real-world clinical applications," said Premal Shah, PhD, CEO, API. "In addition, we have our continued innovation sights set on validating and commercializing new, clinically-relevant panels via a mass spectrometry platform and easy-to-use sample mediums such as dry blood spots. This will dramatically reduce COGS, resulting in increased patient engagement through longitudinal monitoring of a patient's health state—in other words, the body's 'check engine light'."

Details of the poster viewings are as follows:

A new blood test for colorectal cancer in high-risk subjects
Lead/Presenting Author: Lisa J. Croner, PhD
Poster #: A-061
Session: 01/Cancer/Tumor Markers
Date/Time: Aug. 1, 2017 from 9:30 a.m. – 5:00 p.m.

- Continued -

Analytical Validation of a Blood-based Colorectal Cancer and Advanced Adenoma Risk Assessment LDT
Lead/Presenting Author: Roslyn Dillon
Poster #: A-057
Session: 01/Cancer/Tumor Markers
Aug. 1, 2017 from 9:30 a.m. – 5:00 p.m.

Modular Automation for Immunoassays in the Clinical Laboratory
Lead/Presenting Author: Stefanie Kairs
Poster #: B-025
Session: 11/Automation/Computer Applications
Date/Times: Aug. 2, 2017 from 9:30 a.m. – 5:00 p.m.

Applied Proteomics' CEO and the SVP of R&D will be available for one-on-one meetings at the AACC scientific meeting. To schedule a meeting or speak with them in advance of the meeting, please contact Ramune Carothers at rcarothers@appliedproteomics.com or at 949-542-9698.

About SimpliPro Colon
API's SimpliPro Colon test is a blood-based test that assesses the risk for colorectal cancer and advanced adenoma in elevated risk patients. The test is the first commercial application resulting from API's Linus™ technology—a proprietary protein discovery and test delivery engine—and has been utilized by physicians across the nation since its launch in December 2015. In May 2017, API signed an agreement with MultiPlan, Inc., the industry's most comprehensive provider of healthcare cost management solutions, to join its PHCS Network, MultiPlan Network, MultiPlan Workers' Compensation Network, MultiPlan Auto Medical Network and ValuePoint by MultiPlan, providing access to the 50-75 million people who use MultiPlan's networks to the SimpliPro Colon test.

About Applied Proteomics Inc.
Applied Proteomics Inc. develops noninvasive, blood-based tests that leverage the power of the proteome—the body's complete system of proteins—for monitoring and early detection of disease. Our proprietary Linus technology, a protein discovery and test delivery engine, is focused on isolating relevant signals associated with increased risk of disease in a rapid and cost-effective manner to develop highly sensitive and specific diagnostic tests.

###

CONTACT:
Ramuné Carothers
Director of Marketing, Applied Proteomics, Inc.
949-542-9698
rcarothers@appliedproteomics.com
www.appliedproteomics.com